Skip to main content

Table 1 Clinical characteristics of COVID-19 autopsy cohort

From: Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte

  Diabetic patients
(N = 37)
Non-diabetic patients
(N = 60)
P
Age, years 65.9 ± 10.9 69.3 ± 9.4 0.107
Male, n (%) 23 (62.2) 37 (61.7) 0.515
BMI, kg/m2 28.9 ± 6.4 26.2 ± 1.9 0.019
Duration symptoms, days 14.3 ± 1.9 15.1 ± 2.1 0.065
Duration Hospitalization, days 11.3 ± 1.1 9.7 ± 1.2 0.002
Dyslipidemia, n (%) 7 (15.2) 30 (23.7) 0.181
Hypertension, n (%) 23 (62.2) 36 (60.0) 0.502
Obesity, n (%) 15 (40.5) 20 (33.3) 0.307
Cardiovascular disease, n (%) 12 (32.4) 21 (35.0) 0.322
COPD, n (%) 22 (59.5) 34 (56.7) 0.478
Smoking, n (%) 8 (21.6) 12 (20.0) 0.522
Patients with SARS-COV-2 infected cardiomyocytes, n (%) 30 (81.1) 17 (28.3) 0.001
Patients with SARS-COV-2 infected endothelial cells, n (%) 10 (27.0) 22 (36.7) 0.225
Patients with SARS-COV-2 infected macrophages, n (%) 20 (54.1) 41 (68.3) 0.116
Covid-19 drug therapy    
 Antiviral (%) 37 (100) 60 (100) /
 Antibiotics (%) 32 (86.5) 51 (85) 0.396
 Chinidine (%) 30 (81.1) 50 (83.3) 0.512
 Glucocorticoids (%) 29 (78.4) 49 (81.7) 0.215
 Tocilizumab (%) 4 (10.8) 6 (10) 0.510
 Oxygen inhalation (%) 31 (83.8) 50 (83.3) 0.256
  1. Data are means ± SD or n (%)
  2. BMI body mass index, COPD chronic obstructive pulmonary disease, SARS-COV-2 severe acute respiratory syndrome coronavirus 2